By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Pathwork Diagnostics today announced it has closed its $30 million Series C financing.

The round was led by Alta Partners and included existing investors Abingworth, Advent Venture Partners, Novus Ventures, Prospect Venture Partners, and Venrock. David Mack, a director at Alta Partners, has joined the board of Pathwork, the Redwood City, Calif., company said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.